Short answer
Anteris Technologies Global Corp. (AVR) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.2). Item 2.02 text is incomplete and contains only a liability disclaimer.
Anteris Technologies Global Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text is incomplete and contains only a liability disclaimer
- No fiscal 2026 financial results or operating metrics available in the provided excerpt
Item EX-99.1 · Exhibit EX-99.2
- Q2 2026 execution advanced: first U.S. PARADIGM patients enrolled and treated in May 2026
- CMS Medicare reimbursement eligibility removes a key U.S. trial-enrollment barrier under TAVR National Coverage Determination 20.32
- PARADIGM recruitment active across the U.S., Denmark and the Netherlands, with regulatory clearance secured in Canada and France
- Net operating cash outflows reached $20.8 million, while R&D expenses were $23.4 million as trial and manufacturing activities scaled
- Global pivotal trial targets approximately 1,000 patients, comparing DurAVR against commercial TAVRs on one-year clinical outcomes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anteris Technologies Global Corp. 8-K filings
Get the next AVR 8-K as it lands
Follow AVR for push alerts, or ask the research agent what this filing means.